. La-réalisation-d, études pharmacocinétiques serait un pré requis indispensable à la mise en place d'une dose fixe de trastuzumab IV à l'Institut Bergonié Les paramètres cinétiques caractéristiques de l'exposition (AUC, Cmax, Cmin) obtenus après administration d'une dose fixe de trastuzumab IV ne doivent pas différer significativement de ceux obtenus après l'administration d'une dose normalisée au poids du patient. D'autre part, il faudrait s'assurer que les concentrations minimales obtenues soient supérieures à la concentration minimale efficace

O. Mondiale-de and L. Santé, Cancer du sein: prévention et lutte contre la maladie. [En Ligne] 2014, pp.13-15

M. Mousseau, Cancer du sein : épidémiologie, bilan d'extension, modalités thérapeutiques. Médecine nucléaire -Imagerie fonctionnelle et métabolique, 2002.

K. Miller, THE ROLE OF CHEMOTHERAPY FOR METASTATIC BREAST CANCER, Hematology/Oncology Clinics of North America, vol.13, issue.2
DOI : 10.1016/S0889-8588(05)70063-0

. Hematology, Réseau national de cancérologie du Lanquedoc-Roussillon. Référentiel cancers du sein Localement avancé et métastatique, pp.415-434, 1999.

E. Luporsi, Cancer du sein métastatique : stratégies thérapeutiques. Oncologie, pp.2-8, 2007.

K. Hess, Metastatic patterns in adenocarcinoma. Cancer, pp.1624-1633, 2006.

M. Harmer, The TNM-system Aktuelle Probleme in der Chirurgie, pp.25-36, 1970.

S. Singletary, Revision of the American Joint Committee on Cancer Staging System for Breast Cancer, Journal of Clinical Oncology, vol.20, issue.17, pp.3628-3636, 2002.
DOI : 10.1200/JCO.2002.02.026

J. Chang, Survival of patients with metastatic breast carcinoma, Cancer, vol.14, issue.3, pp.545-553, 2003.
DOI : 10.1002/cncr.11083

C. Carter, Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases, Cancer, vol.45, issue.1, pp.181-187, 1989.
DOI : 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H

B. Rack, Patients with recurrent breast cancer: does the primary axillary lymph node status predict more aggressive tumor progression? Breast cancer research and treatment, pp.83-92, 2003.

A. Vincent-salomon, Carcinomes infiltrants : Facteurs pronostiques et prédictifs pour la prise de décision thérapeutique en 2012. [En Ligne] 2014. [Citation : 3-2-2014, F%20pronostic.pdf 21. Balaton. Recommandations pour l'évaluation immunohistochimique des récepteurs hormonaux sur coupes en paraffine dans les carcinomes mammaires, p.336, 1999.

M. Hammond, American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer, Journal of Oncology Practice, vol.6, issue.4, pp.195-197, 2010.
DOI : 10.1200/JOP.777003

P. Wright and G. , Hormone Receptor Status Does Not Affect Prognosis in Metaplastic Breast Cancer: A Population-Based Analysis with Comparison to Infiltrating Ductal and Lobular Carcinomas. Annals of surgical oncology, 2014.

A. Wolff, Recommendations for human epidermal growth factor receptor 2 testing in breast cancerCollege of American Pathologists clinical practice guideline update Archives of pathology & laboratory medicine Experts de la pathologie mammaire. Recommandations pour la Pratique Clinique : Saint Paul de Vence 2007 « cancers du sein ». [En Ligne, pp.241-256, 1976.

H. Lehr, Valeur prédictive de la surexpression/amplification de Her2/neu pour un traitement ciblé du cancer du sein, Revue Medicale Suisse, vol.5, pp.1525-1529, 2009.

D. Slamon, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, vol.235, issue.4785, pp.177-182, 1987.
DOI : 10.1126/science.3798106

S. Ménard, Overexpression and Other Tumor Biologic Variables, Journal of Clinical Oncology, vol.19, issue.2, pp.329-335, 2001.
DOI : 10.1200/JCO.2001.19.2.329

G. Anthony, Cancer du sein triple-négatif : caractéristiques histocliniques et moléculaires, prise en charge et perspectives thérapeutiques, 2013.

G. Clark, Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients., Journal of Clinical Oncology, vol.5, issue.1, pp.55-61, 1987.
DOI : 10.1200/JCO.1987.5.1.55

J. Pierga, Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients, Annals of Oncology, vol.12, issue.2, pp.231-237, 2001.
DOI : 10.1023/A:1008330527188

J. Pierga, Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapy. Cancer, pp.1079-1089, 2001.

D. Blanchard, Association of surgery with improved survival in stage IV breast cancer patients. Annals of surgery, pp.732-738, 2008.

E. Rapiti, Complete Excision of Primary Breast Tumor Improves Survival of Patients With Metastatic Breast Cancer at Diagnosis, Journal of Clinical Oncology, vol.24, issue.18, pp.2743-2749, 2006.
DOI : 10.1200/JCO.2005.04.2226

G. Institut and . Roussy, principes-generaux-de-chirurgie-du-sein-et-des- ganglions-axillaires_1309#sentinelle 36 Institut Gustave Roussy. Cancer du sein Les traitements. [En Ligne] 2014. [Citation : 18-3-0014les-cancers/cancer-du-sein/hormonotherapie 38, Principes généraux de chirurgie du sein et des ganglions axillaires. [En Ligneregion=qc 39. Institut National du CAncer. Les agonistes de la LH-RH. [En Ligne, pp.5-8, 2013.

A. Gabizon, Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes, Cancer research, vol.54, issue.4, pp.987-992, 1994.

. Agence-européenne-du-médicament, Résumé des caractéristiques du produit: Affinitor. [En Ligne] 2014

W. Herve, Cible et mécanismes d'action des anticorps monoclonaux et protéines de fusion. [En Ligne] 2014. [Citation : 11-12-2013

M. K. Gately, Comparison of humanized anti-Tac (Ro 24-7375) and murine anti-Tac Monoclonal antibodies in vitro, 1991.

A. Scheen, Nomenclature internationale des différents types d'anticorps monoclonaux. Revue médicale de Liège, pp.244-247, 2009.

. Vignot-stéphane, Thérapies moléculaires ciblées: De la biologie aux applications cliniques, 2008.

N. Hynes, ERBB receptors and cancer: the complexity of targeted inhibitors. Nature reviews.Cancer, pp.341-354, 2005.

. Namer-moise, Cancer du sein : Compte-rendu du 12ème cours supérieur francophone de cancérologie Nice.Saint-Paul-De-Vence, 2011.

L. Monnier, Ciblage des récepteurs tyrosine kinase membranaires : y a-t-il de la résistance dans l'HER ? Bulletin du cancer, pp.685-694, 2014.

L. Astrid, La voie de signalisation RAS/MAPK. Cancérologie digest, pp.38-42, 2010.

J. Libbey and -. , Therapie Ciblee Des Cancers. 2010. 51. FDA review team. FDA Clinical Review of BLA 98-0369 Herceptin® Trastuzumab (rhuMAb HER2) Clinical Review, 1998.

A. Defazio, Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines, International Journal of Cancer, vol.131, issue.4, pp.487-498, 2000.
DOI : 10.1002/1097-0215(20000815)87:4<487::AID-IJC5>3.0.CO;2-J

D. Brault, La p105 (HER-2 soluble ou ECD) a-t-elle une place dans la prise en charge du cancer du sein? SPECTRA BIOLOGIE, 2005.

Y. Izumi, Tumour biology: Herceptin acts as an anti-angiogenic cocktail, Nature, vol.94, issue.6878, pp.279-280, 2002.
DOI : 10.1038/416279b

. Agence-européenne-du-médicament, Résumé des caractéristiques du produit: Trastuzumab. [En Ligne] 2014. [Citation : 19-11-2013

T. Junttila, Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer cell, pp.429-440, 2009.

G. Valabrega, Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer, Annals of Oncology, vol.18, issue.6, pp.977-984, 2007.
DOI : 10.1093/annonc/mdl475

W. Carney, Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer. Clinical breast cancer, pp.105-116, 2004.

L. Klapper, Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2, Cancer research, vol.60, issue.13, pp.3384-3388, 2000.

J. Sarup, Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth regulation, pp.72-82, 1991.

R. Kumar, The role of HER2 in angiogenesis Seminars in oncology, pp.27-32, 2001.

R. Keizer, Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clinical pharmacokinetics, pp.493-507, 2010.

. Agence-européenne-du-medicament, Note for guidance on the investigation of bioavailability and bioequivalence. Evaluation of Medicines for Human Use Committee of Proprietary Medicinal Products, pp.1-18, 2001.

I. Gustavo, Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. The Lancet Oncology, pp.869-878, 2012.

D. Lévêque, Propriétés pharmacocinétiques des anticorps monoclonaux, Journal de Pharmacie Clinique, vol.21, issue.4, pp.271-277, 2002.

W. Van-osdol, An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a "binding site barrier, Cancer research, vol.51, issue.18, pp.4776-4784, 1991.

C. Genningen, Anticorps monoclonaux à usage thérapeutique en hémato-oncologie. Revue médicale de Liège, pp.264-267, 2009.

F. Brambell, A Theoretical Model of ??-Globulin Catabolism, Nature, vol.203, issue.4952, pp.1352-1354, 1964.
DOI : 10.1038/2031352a0

W. Wang, Monoclonal Antibody Pharmacokinetics and Pharmacodynamics, Clinical Pharmacology & Therapeutics, vol.38, issue.5, pp.548-558, 2008.
DOI : 10.1007/s00280-005-1022-3

M. A. Cobleigh, Multinational study of the efficacy et safety of humanized anti HER2 monoclonal antibody in women who have HER2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease, Journal of clinical oncology, vol.19, pp.2639-2648, 1999.

D. J. Slamon, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England, 2001.

M. Marty, Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2???Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group, Journal of Clinical Oncology, vol.23, issue.19, pp.4265-4274, 2005.
DOI : 10.1200/JCO.2005.04.173

J. Baselga, Phase II Study of Efficacy, Safety, and Pharmacokinetics of Trastuzumab Monotherapy Administered on a 3-Weekly Schedule, Journal of Clinical Oncology, vol.23, issue.10, pp.2162-2171, 2005.
DOI : 10.1200/JCO.2005.01.014

D. Wang, Fixed Dosing Versus Body Size-Based Dosing of Monoclonal Antibodies in Adult Clinical Trials, The Journal of Clinical Pharmacology, vol.56, issue.4, pp.1012-1024, 2009.
DOI : 10.1177/0091270009337512

J. Baselga, Phase I and II clinical trials of trastuzumab, Annals of Oncology, vol.12, issue.suppl 1, pp.49-55, 2001.
DOI : 10.1093/annonc/12.suppl_1.S49

D. Lévêque, Expression des agents anticancéreux en fonction du poids et de la surface corporelle chez l'adulte. Bulletin du cancer, pp.647-651, 2007.

R. Bruno, Population pharmacokinetics of trastuzumab in patients with HER2 metastatic breast cancer. Cancer chemotherapy and pharmacology, pp.361-369, 2005.

S. Bai, A Guide to Rational Dosing of Monoclonal Antibodies, Clinical Pharmacokinetics, vol.317, issue.17, pp.119-135
DOI : 10.2165/11596370-000000000-00000

N. Ismaili, Progr??s r??cents dans les th??rapies cibl??es dans le traitement du cancer du sein m??tastatique HER2-positif, La Presse M??dicale, vol.42, issue.11, pp.1461-1468, 1983.
DOI : 10.1016/j.lpm.2013.01.066

M. Andersson, Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2???Positive Breast Cancer: The HERNATA Study, Journal of Clinical Oncology, vol.29, issue.3, pp.264-271, 2011.
DOI : 10.1200/JCO.2010.30.8213

H. Burstein, Trastuzumab and Vinorelbine as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance Algorithm, Journal of Clinical Oncology, vol.21, issue.15, pp.2889-2895, 2003.
DOI : 10.1200/JCO.2003.02.018

M. Jahanzeb, Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2 (+) metastatic breast cancer. The oncologist, pp.410-417, 2002.

R. Bartsch, Capecitabine and Trastuzumab in Heavily Pretreated Metastatic Breast Cancer, Journal of Clinical Oncology, vol.25, issue.25, pp.3853-3858, 2007.
DOI : 10.1200/JCO.2007.11.9776

G. Schaller, Phase II Study of Capecitabine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2???Overexpressing Metastatic Breast Cancer Pretreated With Anthracyclines or Taxanes, Journal of Clinical Oncology, vol.25, issue.22, pp.3246-3250, 2007.
DOI : 10.1200/JCO.2006.09.6826

A. Chien, The cardiac safety of trastuzumab in the treatment of breast cancer, Expert Opinion on Drug Safety, vol.8, issue.4, pp.335-381
DOI : 10.1007/s11095-007-9425-y